3Zhao W,Zhang J,Lu Y,et al. The vasorelaxant effect of H2S as a novel endogenous gaseous K^+ -ATP channel opener[J]. EMBO J,2001,20(21 ) :6008 - 6016.
4Stipanuk MH, Beck PW. Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat[J].Biochena J, 1982,206: 267-277.
5Rui W. Two's company, three's a crowd:can H2S be the third endogenous gaseous transmitter[J]? FASEB J, 2002, 16:1792-1798.
6Mitani Y, Maruyama K, Sakurai M. Prolonged administration of L-Arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation, 1997;96(2):689～97
7Winberg P, Lundell BP, Gustafsson LE. Effect of inhaled nitric oxide on raised pulmonary vascular resistance in children with congenital heart disease. Br Heart J,1994;71(3):282～6
8Gary UC, Hassid A. Nitric oxide-generating vasodilators and 8-brome-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest, 1989;83(5):1774～7
9Ames RS, Sarau HM, Chambers JK et al. Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature,1999;401(6750):282～6
10MacLean MR, Alexander D, Stirrat A. Constractile responses to human urotensin-Ⅱ in rat and human pulmonary arteries: Effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol,2000;130(2):201～4
2Reithmann C, Reber D, Kozlik-Feldmann R.Post-receptor de- fect of adenylyl cyclase in severely failing myocardium from chil- dren with congenital heart disease [J].Eur J Pharmacol, 1997, 330: 79-86.
3Stephanie L, Thorns S, Frederike B, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investi- gating clinical and pharmacokinetic parameters [J ].Am Heart J, 2002,143: 916-922.
4Jianwen W, Kalpana P, Chandra B, et al. Comparison of novel echocardiographic parameters of right ventricular function with ejection fraction by cardiac magnetic resonance [J]. J Am Soc Echocardiogr, 2007,20:1058-1064.
5Rabionovitch M. Cellular and molecular pathobiology of pulmo- nary hypertension conference summary [J]. Chest, 2005, 128 (6) : 642-646.
6Habib G, Torbicki A.The role of echocardiography in the diagno- sis and management of patients with pulmonary hypertension [J].Eur Respir Rev, 2010,19(118) :288-299.
7Watanabe M, Ono S, Tomomasa T, et al.Measurement of tricus- pid annular diastolic velocities by Doppler tissue imaging to as- sess right ventricular function in patients with congenital heart disease [ J ] .Pediatr Cardiol, 2003,24 (5) : 463-467.
8Tayyareci Y, Nisanci Y, Umman B, et al. Early detection of right ventricular systolic dysfunction by using myocardial acceleration during isovolumic contraction in patients with mitral stenosis [J 3. Eur J Echocardiogr, 2008, 9 : 516-521.
9Nell S, Navin R, Kathy E, et al. Tricuspid annular systolic ve- locity: a useful measurement in determining right ventricular systolic function regardless of pulmonary artery pressures [J]. Echocardiography, 2006, 23 ( 1 ) : 750-755.
10Kjaergaard J, Snyder EM, Hassager C, et al. Impact of pre- load and afterload on global and regional right ventricular func- tion and pressure : a quantitative echocardiography study [ J ]. J Am Soc Echocardiol, 2006, 19(5) :515-521.
